

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

54-56. (Canceled)

58-68. (Canceled)

New claims

69. (New) A method for reducing T cell responsiveness *in vivo* to an autoantigen expressing cell, which method comprises administering to a subject in need of such treatment:

- (a) an antigen-presenting cell that presents an autoantigen; and
- (b) an anti-gp39 antibody which binds to an antigen, which antigen:
 - (i) is bound by MR1, wherein MR1 is a monoclonal antibody produced by a hybridoma having ATCC Accession No. HB 11048;
 - (ii) is present on activated but not resting T-cells; and
 - (iii) has the same molecular weight as a protein precipitated by a CD40-immunoglobulin (CD40-Ig) fusion protein,

wherein the anti-gp39 antibody is administered prior to, concurrent with, or subsequent to administration of the antigen-presenting cell in an amount effective to reduce T cell responsiveness to the antigen-presenting cell.

70. (New) The method of claim 69, wherein the antigen-presenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.

71. (New) The method of claim 69, wherein the antigen-presenting cell is a B lymphocyte.

72. (New) The method of claim 71, wherein the B lymphocyte is an activated B lymphocyte.

73. (New) The method of claim 72, wherein the activated B lymphocyte is a splenic activated B lymphocyte.

74. (New) The method of claim 69, wherein the antigen-presenting cell is a lymphoid cell.

75. (New) The method of claim 69, wherein the antigen-presenting cell is a peripheral blood lymphocyte.

76. (New) The method of claim 69, wherein the antigen-presenting cell is a bone marrow lymphocyte.

77. (New) The method of claim 69, wherein the antigen-presenting cell is a Langerhans cell.

78. (New) The method of claim 69, wherein the antigen-presenting cell is a dendritic cell.

79. (New) The method of claim 69, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.

80. (New) The method of claim 79, wherein the anti-human anti-gp39 antibody is humanized.

81. (New) The method of claim 79, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.